

## EQA round: IHC2/24 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 6.9.2024

Setup: groups - R (manufacturer of kit)

AV = assigned value	N <sub>tot</sub> = total number of the results	N <sub>eva</sub> = number of the results assessed
CVE = consensus of the experts	N <sub>rel</sub> = relative number of the results	N <sub>suc</sub> = number of successful results
>>> ... expected result		S <sub>rel</sub> = relative success
> ... acceptable result		
± ... result not assessed		

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(601) A1 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	7	16	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	10	23	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	61	Strong positive (3+)			
<b>(602) A2 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	2	4,5	Negative (0)			
	>	5	11	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	6	14	Negative (0)			
	>	4	9,1	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	61	Negative (0)			
<b>(603) A3 expression HER-2/neu</b>		40			40	34	85
<b>Slide</b>		40			40	34	85
(802) Dako HercepTest	CVE >>>	5	13	Weak positive (2+)			
	>	2	5	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein		1	2,5	Negative (1+)			
	CVE >>>	6	15	Weak positive (2+)			
	>	2	5	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		5	13	Negative (1+)			
	CVE >>>	19	48	Weak positive (2+)			
<b>(606) B1 expression HER-2/neu</b>		44			44	39	89
<b>Slide</b>		44			44	39	89
(802) Dako HercepTest		1	2,3	Negative (1+)			
	CVE >>>	6	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein		1	2,3	Negative (1+)			
	CVE >>>	7	16	Weak positive (2+)			
	>	2	4,5	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		3	6,8	Negative (1+)			
	CVE >>>	24	55	Weak positive (2+)			
<b>(607) B2 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	3	6,8	Weak positive (2+)			
	CVE >>>	4	9,1	Strong positive (3+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	2	4,5	Weak positive (2+)			
	CVE >>>	8	18	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	9	20	Weak positive (2+)			
	CVE >>>	18	41	Strong positive (3+)			
<b>(608) B3 expression HER-2/neu</b>		44			0		
<b>Slide</b>		44			0		
(802) Dako HercepTest	±	1	2,3	Negative (1+)			
	±	6	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	3	6,8	Negative (1+)			
	±	7	16	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	12	27	Negative (1+)			
	±	15	34	Weak positive (2+)			
<b>(611) C1 expression HER-2/neu</b>		44			44	40	91
<b>Slide</b>		44			44	40	91
(802) Dako HercepTest	CVE >>>	7	16	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein		3	6,8	Negative (1+)			
	CVE >>>	6	14	Weak positive (2+)			
	>	1	2,3	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu		1	2,3	Negative (1+)			
	CVE >>>	24	55	Weak positive (2+)			
	>	2	4,5	Strong positive (3+)			
<b>(612) C2 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	1	2,3	Negative (0)			
	CVE >>>	6	14	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	3	6,8	Negative (0)			
	CVE >>>	7	16	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	16	36	Negative (0)			
	CVE >>>	11	25	Negative (1+)			

## EQA round: IHC2/24 - Immunohistochemistry - Detection of HER-2/neu

Deadline: 6.9.2024

Setup: groups - R (manufacturer of kit)

Test Sample Group	Frequency of the results			Success			
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(613) C3 expression HER-2/neu</b>		44			44	43	98
<b>Slide</b>		44			44	43	98
(802) Dako HercepTest		1	2,3	Negative (1+)			
	CVE >>>	6	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	11	Weak positive (2+)			
	CVE >>>	5	11	Strong positive (3+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	17	39	Weak positive (2+)			
	CVE >>>	10	23	Strong positive (3+)			
<b>(616) D1 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	7	16	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	8	18	Negative (0)			
	CVE >>>	2	4,5	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	15	34	Negative (0)			
	CVE >>>	12	27	Negative (1+)			
<b>(617) D2 expression HER-2/neu</b>		44			0		
<b>Slide</b>		44			0		
(802) Dako HercepTest	±	4	9,1	Negative (1+)			
	±	3	6,8	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	±	3	6,8	Negative (1+)			
	±	7	16	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu	±	13	30	Negative (1+)			
	±	14	32	Weak positive (2+)			
<b>(618) D3 expression HER-2/neu</b>		44			44	38	86
<b>Slide</b>		44			44	38	86
(802) Dako HercepTest		1	2,3	Negative (1+)			
	CVE >>>	6	14	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein		3	6,8	Negative (1+)			
	CVE >>>	7	16	Weak positive (2+)			
(804) Ventana PATHWAY anti-HER-2/neu		2	4,5	Negative (1+)			
	CVE >>>	21	48	Weak positive (2+)			
	>	4	9,1	Strong positive (3+)			
<b>(621) E1 expression HER-2/neu</b>		44			44	43	98
<b>Slide</b>		44			44	43	98
(802) Dako HercepTest	CVE >>>	3	6,8	Negative (0)			
	CVE >>>	3	6,8	Negative (1+)			
		1	2,3	Weak positive (2+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	6	14	Negative (0)			
	CVE >>>	4	9,1	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	22	50	Negative (0)			
	CVE >>>	5	11	Negative (1+)			
<b>(622) E2 expression HER-2/neu</b>		44			44	41	93
<b>Slide</b>		44			44	41	93
(802) Dako HercepTest	CVE >>>	4	9,1	Negative (0)			
	CVE >>>	3	6,8	Negative (1+)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	5	11	Negative (0)			
	CVE >>>	5	11	Negative (1+)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	8	18	Negative (0)			
	CVE >>>	16	36	Negative (1+)			
		3	6,8	Weak positive (2+)			
<b>(623) E3 expression HER-2/neu</b>		44			44	44	100
<b>Slide</b>		44			44	44	100
(802) Dako HercepTest	CVE >>>	7	16	Negative (0)			
(803) Dako c-erbB-2 Onkoprotein	CVE >>>	10	23	Negative (0)			
(804) Ventana PATHWAY anti-HER-2/neu	CVE >>>	27	61	Negative (0)			